• Arroyo S, De La Morena A. (2001) Life-threatening adverse events of antiepileptic drugs. Epilepsy Research 47:155174.
  • Bunce M, O'Neill CM, Barnardo MC, Krausa P, Browning MJ, Morris PJ, Welsh KI. (1995) Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 46:355367.
  • Chadwick D, Shaw MD, Foy P, Rawlins MD, Turnbull DM. (1984) Serum anticonvulsant concentrations and the risk of drug induced skin eruptions. Journal of Neurolology, Neurosurgery and Psychiatry 47:642644.
  • Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT. (2004) Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428:486.
  • Guberman AH, Besag FM, Brodie MJ, Dooley JM, Duchowny MS, Pellock JM, Richens A, Stern RS, Trevathan E. (1999) Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 40:985991.
  • Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR, Hu SL, Wu MT, Chen GS, Wong TW, Hsiao PF, Chen WH, Shih HY, Fang WH, Wei CY, Lou YH, Huang YL, Lin JJ, Chen YT. (2006) Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenetics and Genomics 16:297306.
  • Jewell NP. (1986) On the bias of commonly used measures of association for 2x2 tables. Biometrics 42:351358.
  • Lonjou C, Thomas L, Borot N, Ledger N, De Toma C, LeLouet H, Graf E, Schumacher M, Hovnanian A, Mockenhaupt M, Roujeau JC, RegiSCAR Group. (2006) A marker for Stevens-Johnson syndrome …: ethnicity matters. Pharmacogenomics Journal 6:265268.
  • Naisbitt DJ, Britschgi M, Wong G, Farrell J, Depta JP, Chadwick DW, Pichler WJ, Pirmohamed M, Park BK. (2003) Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Molecular Pharmacology 63:732741.
  • Nassif A, Bensussan A, Boumsell L, Deniaud A, Moslehi H, Wolkenstein P, Bagot M, Roujeau JC. (2004) Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. Journal of Allergy and Clinical Immunology 114:12091215.
  • Svensson CK, Cowen EW, Gaspari AA. (2000) Cutaneous Drug Reactions. Pharmacological Reviews 53:357379.
  • Tennis P, Stern RS. (1997) Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 49:542546.
  • Wu Y, Sanderson JP, Farrell J, Drummond NS, Hanson A, Bowkett E, Berry N, Stachulski AV, Clarke SE, Pichler WJ, Pirmohamed M, Park BK, Naisbitt DJ. (2006) Activation of T cells by carbamazepine and carbamazepine metabolites. Journal of Allergy and Clinical Immunology 118:233241.